Biopharma Leaders Unite To Stand With Science LEARN MORE Pfizer & BioNTech to Supply Singapore with Vaccine Candidate to Combat COVID-19 LEARN MORE PFIZER INVESTS $120MIL IN BIOTECH INNOVATION LEARN MORE Pfizer Confirms U.S. Patent Term Extension for IBRANCE® (palbociclib) Until March 2027 LEARN MORE AGREEMENT REACHED WITH COVAX FOR ADVANCE PURCHASE OF COVID-19 VACCINE LEARN MORE RECENT PRESS RELEASES 08/01/2021 - An In Vitro Study Shows Pfizer-BioNTech COVID-19 Vaccine Elicits Antibodies that Neutralize SARS-CoV-2 with a Mutation Associated with Rapid Transmission 07/01/2021 - Pfizer Doses First Participant in Phase 3 Study for Duchenne Muscular Dystrophy Investigational Gene Therapy 05/01/2021 - Pfizer Invites Public to Listen to Two Webcasts of Pfizer Discussions at Healthcare Conference 04/01/2021 - US FDA Accepts Regulatory Submission from Pfizer and OPKO for Review of Somatrogon to Treat Pediatric Patients with Growth Hormone Deficiency 29/12/2020 - Pfizer and BioNTech to Supply the European Union with 100 Million Additional Doses of COMIRNATY® 28/12/2020 - LORBRENA® (lorlatinib) sNDA in Previously Untreated ALK-Positive Lung Cancer Accepted for Priority Review by U.S. FDA 28/12/2020 - Myovant Sciences and Pfizer Announce Collaboration to Develop and Commercialize Relugolix in Oncology and Women's Health 23/12/2020 - Pfizer and BioNTech to Supply the U.S. with 100 Million Additional Doses of COVID-19 Vaccine 22/12/2020 - Pfizer Invites Public to View and Listen to Webcast of February 2 Conference Call with Analysts 21/12/2020 - Pfizer and BioNTech Receive Authorization in the European Union for COVID-19 Vaccine 21/12/2020 - Pfizer and BioNTech Receive CHMP Positive Opinion for their COVID-19 Vaccine 14/12/2020 - Pfizer and BioNTech to Supply Singapore with their BNT162b2 mRNA-based Vaccine Candidate to Combat COVID-19 14/12/2020 - Pfizer and BioNTech Provide Data from German Phase 1/2 Study Further Characterizing Immune Response Following Immunization with Lead COVID-19 Vaccine Candidate BNT162b2 12/12/2020 - U.S. CDC Committee of Independent Health Experts Recommends Vaccination with Pfizer and BioNTech COVID-19 Vaccine for Persons Ages 16 Years and Older 12/12/2020 - Pfizer and BioNTech Celebrate Historic First Authorization in the U.S. of Vaccine to Prevent COVID-19 Pagination First page « First Previous page ‹ Previous Page 1 Page 2 Current page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 Next page Next › Last page Last »
